Search

Byline: Laura. Serra-García, Paola. Castillo, Pilar. Iranzo, Josep. Riera-Monroig A 79-year-old woman with a two-year history of unexplained progressive cholestasis was admitted to the hospital suffering from jaundice, abdominal pain, [...]

Sweet syndrome is a neutrophilic dermatosis associated with multiple disorders. This retrospective case-series study of patients with Sweet syndrome in a tertiary hospital in Spain from 2001 to 2021, explores clinicopathological characteristics of Sweet syndrome and variables associated with malignancy, presence of autoinflammatory disorders and differences between histological subtypes. A total of 93 patients were identified: 30% idiopathic, 34% malignancy-associated, 29% reactive to infections or drug-associated, and 6% with an autoimmune/inflammatory condition. Acute myeloid leukaemia was the most common malignancy (16/93) followed by myelodysplastic syndrome (7/93). Patients with acute myeloid leukaemia presented isolated flares, marked cytopaenia and rapid response to treatment, whereas myelodysplastic syndrome followed a chronic-recurrent course. The most frequent associated medications and inflammatory disorders were filgrastim and hydroxyurea (n=2); and inflammatory bowel disease (n=4). In addition, 3 patients were diagnosed with VEXAS syndrome. Male sex (p=0.006), fever (p=0.034), increased erythrocyte sedimentation rate (p<0.001), anaemia (p<0.001), and thrombocytopaenia (p<0.001) were associated with malignancy. Histologically, patients were classified as classic (60%), histiocytoid (22.5%) or subcutaneous (15%), with pain (p=0.011) and nodules (p<0.001) being associated with subcutaneous-Sweet syndrome. Sweet syndrome in the context of cytopaenia should alert the presence of malignancy. An acquired autoinflammatory condition should be explored in relapsing Sweet syndrome with myelodysplastic syndrome. A minimum follow-up of 6 months is recommended. [ABSTRACT FROM AUTHOR]

Acral melanoma is the fourth most common subtype of cutaneous melanoma in Caucasians, representing 2-3% of all melanomas,1 but is the most frequent histological subtype among non-Caucasians and dark-skinned populations.2 It is found on glabrous skin of the soles, palms and nailbeds, with 80% appearing on the feet. Compared to other subtypes of cutaneous melanoma, it has a worse prognosis, with significantly lower 5-year melanoma-specific survival rates.1 This fact has been mainly attributed to delayed diagnosis, which is well documented in the literature, and can average as much as 18 months.2 Moreover, the diagnosis of acral melanoma remains challenging for many reasons. Dermoscopy training course improves podiatrists' accuracy in diagnosing lesions suggestive of acral melanoma: A cross-sectional study. [Extracted from the article]

Keywords: hydrochlorothiazide; photo-induced purpura; solar capillaritis; solar purpura EN hydrochlorothiazide photo-induced purpura solar capillaritis solar purpura 82 84 3 01/17/23 20230101 NES 230101 Solar capillaritis (also referred to as solar purpura) is a rare phenomenon consisting in the appearance of acute purpuric lesions related to solar exposure. Hydrochlorothiazide, photo-induced purpura, solar capillaritis, solar purpura 1988; 5 (1): 47 - 48. 4 Kalivas J, Kalivas L. Solar purpura appearing in a patient with polymorphous light eruption. [Extracted from the article]

Keywords: acquired erythropoietic uroporphyria; Günther's disease; myeloid malignancy; porphyria cutanea tarda EN acquired erythropoietic uroporphyria Günther's disease myeloid malignancy porphyria cutanea tarda 86 91 6 01/18/22 20220101 NES 220101 CONFLICT OF INTEREST None declared. This shows the importance of performing specific blood and urinary porphyrin quantification and using isomer separation laboratory techniques, which will reveal elevated urinary and erythrocytary type I porphyrin isomers, instead of the type III porphyrin isomers found in PCT.2 The presence of uroporphyrins within red blood cells demonstrates the hematologic origin of the disorder. [Extracted from the article]

Dear Editor, Cutaneous manifestations of coronavirus disease 2019 (COVID-19), including pseudo-chilblain, vesicular, maculopapular, urticaria, and livedo/necrosis1 lesions, have been widely reported. Other patients with COVID-19 and thrombotic events develop antiphospholipid antibodies, suggesting an antiphospholipid syndrome-like condition.5 Cemiplimab is a novel anti-PD-1 therapy recently approved for locally advanced or metastatic cutaneous SCC. [Extracted from the article]